Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue suppl 6, Pages vi64-vi72
Publisher
Oxford University Press (OUP)
Online
2013-09-27
DOI
10.1093/annonc/mdt354
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Age on the Efficacy of Newer Adjuvant Therapies in Patients With Stage II/III Colon Cancer: Findings From the ACCENT Database
- (2013) Nadine J. McCleary et al. JOURNAL OF CLINICAL ONCOLOGY
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- (2012) H. J. Schmoll et al. ANNALS OF ONCOLOGY
- Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer
- (2012) Daniel J. Sargent JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial
- (2012) Christophe Tournigand et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
- (2012) A. D. Roth et al. JNCI-Journal of the National Cancer Institute
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Aspirin Use, TumorPIK3CAMutation, and Colorectal-Cancer Survival
- (2012) Xiaoyun Liao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Models of care for post-treatment follow-up of adult cancer survivors: a systematic review and quality appraisal of the evidence
- (2012) D. Howell et al. Journal of Cancer Survivorship
- Continuity of care of colorectal cancer survivors at the end of treatment: the oncology–primary care interface
- (2012) Jeffrey J. Sisler et al. Journal of Cancer Survivorship
- A Framework for Cancer Survivorship Research and Translation to Policy
- (2011) E. Grunfeld et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- (2011) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
- Is It Time to Lower the Recommended Screening Age for Colorectal Cancer?
- (2011) Donald M. Davis et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Microsatellite Instability, Prognosis and Drug Sensitivity of Stage II and III Colorectal Cancer: More Complexity to the Puzzle
- (2011) S. Tejpar et al. JNCI-Journal of the National Cancer Institute
- C-stage in Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker in Staging, Prognosis, and Management
- (2011) Pragatheeshwar Thirunavukarasu et al. JNCI-Journal of the National Cancer Institute
- DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
- (2011) F. A. Sinicrope et al. JNCI-Journal of the National Cancer Institute
- Global Patterns of Cancer Incidence and Mortality Rates and Trends
- (2010) A. Jemal et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Recent trends in colorectal cancer mortality in Europe
- (2010) Cristina Bosetti et al. INTERNATIONAL JOURNAL OF CANCER
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
- (2010) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Diagnostic Imaging of Colorectal Liver Metastases with CT, MR Imaging, FDG PET, and/or FDG PET/CT: A Meta-Analysis of Prospective Studies Including Patients Who Have Not Previously Undergone Treatment
- (2010) Maarten Christian Niekel et al. RADIOLOGY
- International Trends in Colorectal Cancer Incidence Rates
- (2009) M. M. Center et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Postoperative Surveillance Recommendations for Early Stage Colon Cancer Based on Results From the Clinical Outcomes of Surgical Therapy Trial
- (2009) Vassiliki L. Tsikitis et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- (2009) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Short-Term Outcomes of the Australasian Randomized Clinical Study Comparing Laparoscopic and Conventional Open Surgical Treatments for Colon Cancer
- (2008) Peter J. Hewett et al. ANNALS OF SURGERY
- Evaluation of Preoperative Computed Tomography in Estimating Peritoneal Cancer Index in Colorectal Peritoneal Carcinomatosis
- (2008) Ju-Li Koh et al. ANNALS OF SURGICAL ONCOLOGY
- Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis
- (2008) A C Ford et al. GUT
- Individualized Prediction of Colon Cancer Recurrence Using a Nomogram
- (2008) Martin R. Weiser et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer survival in five continents: a worldwide population-based study (CONCORD)
- (2008) Michel P Coleman et al. LANCET ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started